Dry eye drug from Inspire gets patent extension in Japan | Lastest “Eye” News

Dry eye drug from Inspire gets patent extension in Japan
Two dry eye therapy patents owned by Inspire Pharmaceuticals (NASDAQ:ISPH) have received extensions in Japan, which gives the drug Diquas patent protection until February 2023. Raleigh, North Carolina-based Inspire disclosed in a securities filing that the extension gives one Diquas patent an additional five years of exclusivity; another patent received approximately 4.5 years of exclusivity …
Read more on MedCity News

Posts Related to Dry eye drug from Inspire gets patent extension in Japan | Lastest “Eye” News